|
gptkbp:instanceOf
|
gptkb:drug
histamine H2-receptor antagonist
|
|
gptkbp:approvalYear
|
1981
|
|
gptkbp:approvedBy
|
gptkb:United_Kingdom
|
|
gptkbp:ATCCode
|
gptkb:A02BA02
|
|
gptkbp:brand
|
gptkb:Zantac
gptkb:Acidil
Ranitab
|
|
gptkbp:CASNumber
|
gptkb:66357-35-5
|
|
gptkbp:chemicalClass
|
gptkb:furan
nitro compound
thioether
|
|
gptkbp:contraindication
|
hypersensitivity to ranitidine
|
|
gptkbp:discoveredBy
|
gptkb:Glaxo_Holdings
|
|
gptkbp:eliminationHalfLife
|
2-3 hours
|
|
gptkbp:excretion
|
gptkb:kidney
|
|
gptkbp:form
|
gptkb:sugar
gptkb:tablet
injection
|
|
gptkbp:hasMolecularFormula
|
C13H22N4O3S
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Ranitidine
|
|
gptkbp:introducedIn
|
1981
|
|
gptkbp:legalStatus
|
withdrawn in many countries
|
|
gptkbp:mechanismOfAction
|
blocks H2 receptors in stomach
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:patent
|
gptkb:Glaxo_Holdings
|
|
gptkbp:pregnancyCategory
|
B (US)
|
|
gptkbp:replacedBy
|
gptkb:proton_pump_inhibitors
gptkb:famotidine
other H2 blockers
|
|
gptkbp:retired
|
NDMA contamination
|
|
gptkbp:routeOfAdministration
|
oral
intramuscular
intravenous
|
|
gptkbp:sideEffect
|
diarrhea
constipation
dizziness
fatigue
headache
rash
|
|
gptkbp:status
|
withdrawn from EU market
withdrawn from India market
withdrawn from US market
|
|
gptkbp:usedFor
|
treating gastroesophageal reflux disease
treating Zollinger-Ellison syndrome
treating peptic ulcer disease
reducing stomach acid
|
|
gptkbp:WHOModelListOfEssentialMedicines
|
yes
|
|
gptkbp:bfsParent
|
gptkb:CHEMBL1487
gptkb:Zentiva
|
|
gptkbp:bfsLayer
|
7
|